Adding high-dose celecoxib to increase effectiveness of standard glioblastoma chemoirradiation
Author:
- 1 September 2021
- journal article
- review article
- Published by Elsevier in Annales Pharmaceutiques Françaises
- Vol. 79 (5) , 481-488
Abstract
No abstract availableKeywords
This publication has 80 references indexed in Scilit:
- Carbonic Anhydrase IX Promotes Tumor Growth and NecrosisIn Vivoand Inhibition Enhances Anti-VEGF TherapyClinical Cancer Research, 2012
- Celecoxib pathwaysPharmacogenetics and Genomics, 2012
- Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancerCancer, 2011
- Deficient carbonic anhydrase 9 expression in UPR-impaired cells is associated with reduced survival in an acidic microenvironmentRadiotherapy and Oncology, 2009
- Carbonic anhydrase IX and response to postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of the DBCG82 b and c trialsBreast Cancer Research, 2008
- A Phase I Trial to Determine the Optimal Biological Dose of Celecoxib when Combined with Erlotinib in Advanced Non–Small Cell Lung CancerClinical Cancer Research, 2006
- Expression of Carbonic Anhydrase IX in Astrocytic Tumors Predicts Poor PrognosisClinical Cancer Research, 2006
- Clinical Pharmacokinetics and Pharmacodynamics of CelecoxibClinical Pharmacokinetics, 2000
- Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: What can we expect?Scandinavian Journal of Rheumatology, 1999
- Measurement of Regional Cerebral pH in Human Subjects Using Continuous Inhalation of 11CO2 and Positron Emission TomographyJournal of Cerebral Blood Flow & Metabolism, 1984